Wegovy 1.0mg: the dose that asks you to make a decision

Why the 1.0mg dose is a genuine decision point, not just a waypoint

The titration schedule for Wegovy is not arbitrary. Each step (0.25mg, 0.5mg, 1.0mg, 1.7mg, 2.4mg) exists because semaglutide's GI effects are dose-dependent. Moving too quickly compounds nausea and can lead to people stopping altogether; moving too slowly risks unnecessary delay in reaching a dose that produces meaningful appetite suppression.

At 1.0mg, something shifts. This is the dose where many people first notice a clearer change in hunger signals: meals feel more satisfying at smaller portions, and the impulse to snack between them is reduced more noticeably than at 0.5mg. That is not guaranteed, and individual responses vary considerably. But it is also the dose where, if side effects have been persistent or difficult, a prescriber may decide to hold rather than advance, staying at 1.0mg for longer than the standard four-week window before stepping up.

That flexibility is deliberate. The Wegovy treatment overview explains how the schedule works across the full titration, but the key practical point is this: the pace is guided by tolerability and clinical response, and it is your prescriber's call. If you have had persistent nausea, vomiting or significant fatigue at 0.5mg, the 1.0mg step is the right moment to flag that before advancing. Holding at a dose is a clinical decision, not a setback.

What semaglutide is actually doing at this dose level

Semaglutide activates GLP-1 receptors in the gut and brain. In the gut, it slows the rate at which the stomach empties, which is partly why people feel fuller for longer and partly why nausea is the most commonly reported side effect early in treatment. In the brain, it acts on appetite-regulating pathways in the hypothalamus, reducing the reward response to food and dampening the background noise of hunger that many people on treatment describe as having been constant before.

At 1.0mg, semaglutide's blood concentration is meaningfully higher than at 0.5mg, and this is reflected in the clinical trial data. The STEP 1 trial, published in the New England Journal of Medicine, followed adults on the full 2.4mg maintenance dose over 68 weeks and reported around 15% average body-weight reduction. The 1.0mg dose is not the endpoint of that trial (it is a step through it) but understanding what the mechanism is doing helps explain why rushing the titration rarely serves patients well. The appetite changes at 1.0mg are real and worth noticing; they also tend to intensify as the dose climbs.

One practical note: Wegovy pens are stored in the fridge, and many people find it easiest to keep the current pen in the fridge door, it is visible, accessible and less likely to be accidentally frozen. For information on what to do if a dose is missed or a pen has been stored incorrectly, the Patient Information Leaflet that comes with your medication is the authoritative guide.

Side effects at 1.0mg: what is normal and what warrants a call

By the 1.0mg stage, most people have a reasonable sense of how their body responds to semaglutide's GI effects. Nausea, loose stools, constipation, and burping are all reported across the titration range, and they do not necessarily worsen at 1.0mg compared to earlier doses, for many people they are already easing. Fatigue and mild headache are also noted, particularly in the days following an injection.

The picture to watch for is not mild nausea but something more persistent or severe. The MHRA Yellow Card scheme exists for patients to report suspected side effects, something worth knowing if you experience anything unexpected. More urgently, severe stomach pain that radiates to the back, with or without vomiting, should prompt immediate medical attention; this pattern can indicate pancreatitis, which is a rare but recognised serious side effect across GLP-1 medicines.

At 1.0mg, dehydration from persistent vomiting or diarrhoea is also worth monitoring. Staying hydrated is practical advice that applies across all doses, not just this one. If you are uncertain whether what you are experiencing is within the expected range, our clinical support team is available seven days a week. The same applies to questions about changes in urination, which some people notice and find surprising on GLP-1 treatment.

What comes after 1.0mg, and how that affects decisions now

Most people on the standard Wegovy schedule step to 1.7mg after four weeks at 1.0mg, and then to 2.4mg (the maintenance dose studied in STEP 1) four weeks after that. The newer higher-dose pathway extends further, with the 7.2mg pen approved by the MHRA in April 2026 for adults with a BMI of 30 or above.

Knowing what comes after 1.0mg matters for a specific reason: if this dose has been uncomfortable, stepping up will increase the GI load further. A prescriber who knows your current experience can plan accordingly, slowing progression, adjusting injection timing, or advising on dietary adjustments that reduce the likelihood of nausea at higher doses. That is clinical reasoning, not gatekeeping. If you want a closer look at what the next stage involves, our Wegovy 1.2mg page covers what to expect as you move through that part of the titration, and our Wegovy 1.0mg guide goes into more detail on this specific dose for anyone who wants to read further before their next injection.

For people considering Wegovy for the first time, understanding the cost structure of private treatment is a reasonable part of that planning. A prescription is required from a registered prescriber before any dose, including 1.0mg, can be dispensed. If you would like to understand whether Wegovy is likely to be clinically suitable for you, speaking to our prescribers is the right starting point, consultations are free, and reviewed the same day by a GPhC-registered clinician, not software.